AltPep develops early disease-modifying treatments and detection tools for amyloid diseases.
Our lead programs aim to identify Alzheimer’s disease and Parkinson’s disease long before symptoms occur and then neutralize toxic soluble oligomers associated with these diseases.
The AltPep platform, the foundation of our diagnostic and therapeutic programs, is based on a library of custom designed synthetic peptides. This growing library is being used to target one of the earliest molecular triggers of amyloid diseases.
Highly sensitive, simple blood tests in development to aid in the early detection of amyloid diseases.
In development for use in concert with early detection to target and neutralize the toxic soluble oligomers associated with amyloid diseases.
Recent News and Events
“Amyloid diseases are linked to protein misfolding whereby the amyloidogenic protein undergoes a conformational change, aggregates and eventually forms amyloid fibrils…”
Lecture at UW on Oct 13, 2022 with Valerie Daggett, AltPep CEO. Learn about her groundbreaking work in Alzheimer’s and other amyloid…
Alzheimer’s disease researchers were buoyed by positive data released Tuesday from a large clinical trial of an experimental therapy being developed by Biogen and Eisai.
The early data suggest that the treatment, called lecanemab, eases cognitive decline. The findings also rejuvenated hope in a therapeutic approach targeting peptides that form nasty clumps in the brain of people with Alzheimer’s.
The news: University of Washington spinout AltPep recently raised $44.4 million, according to a regulatory filing. The company declined to discuss the filing, but founder and CEO Valerie Daggett spoke with GeekWire about AltPep’s progress on its experimental blood test to detect Alzheimer’s disease at the earliest stages.
Alzheimer’s Disease (AD) is a neurodegenerative disorder that is characterized clinically by progressive cognitive decline and pathologically by the β-sheet rich fibril plaque deposition of the amyloid-β (Aβ) peptide in the brain. While plaques are a hallmark of AD, plaque burden is not correlated with cognitive impairment. Instead, Aβ oligomers formed during the aggregation process represent the main agents of neurotoxicity, which occurs 10–20 years before patients begin to show symptoms…